Soy protein health claim
This article was originally published in The Tan Sheet
Executive Summary
On behalf of the soybean producing industry, Rep. Ed Bryant (R-Tenn.) sends letter to FDA Commissioner Jane Henney, MD, Jan. 11 supporting the agency's Nov. 10 proposed rule allowing a heart disease risk reduction claim for soy protein products ("The Tan Sheet" Nov. 16, 1998, p. 4). Co-signed by more than 40 members of Congress, the letter notes the Soybean Industry Coalition has completed 46 clinical studies demonstrating the substance "significantly reduces" total LDL cholesterol without affecting beneficial HDL-cholesterol, and the "evidence weighs strongly in favor of soy protein with naturally occurring isoflavones as being the agent of the observed lipid-lowering effects." The comment period of the proposal closes Jan. 25
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning